

**ProteoTech's Chief Scientific Officer, Dr. Alan Snow, to Present at the 8th
Annual International Drug Discovery Congress of Sciences and Technology:
*October 23-26, 2010***

ProteoTech, Inc. today announced that the Company's President and Chief Scientific Officer, Alan D. Snow, Ph.D., will give two presentations at the 8th Annual International Drug Discovery Congress of Sciences and Technology in Beijing, China. The first presentation is on October 23, 2010 at 2:45pm and is entitled:

*Development of Synuclere[™]: A Novel Disease-Modifying Drug for the
Reduction of Brain Alpha-Synuclein Aggregates in Parkinson's Disease*

Dr. Snow will also be giving a second presentation on October 26th at 9:30am entitled:

*Development of Neuromaxin[™]: A Concentrated Plant Extract Developed
for Memory Enhancement and Brain Amyloid Plaque Reduction*

Both of Dr. Snow's presentations will be held at the Beijing International Convention Center (BICC), Beijing, China. Website: <http://www.iddst.com/2010>

About ProteoTech: ProteoTech is a private drug development company founded in 1996 located in the Seattle, WA area (Kirkland, WA), and is focused on targeting amyloid diseases. Besides Synuclere[™] for Parkinson's disease treatment and Neuromaxin[™], the Company is also advancing EXEBRYL-1[®] for the treatment of Alzheimer's disease, Systebryl[™] for the treatment of Systemic Amyloidosis, and is in late stage pre-clinical development of a novel small peptide called PeptiClere[™] for the treatment of Alzheimer's disease. For more information, please see the Company web site at www.proteotech.com.